Spots Global Cancer Trial Database for peripheral blood draw
Every month we try and update this database with for peripheral blood draw cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Minimal Residual Disease in Peripheral T-cell Lymphoma | NCT03297697 | Peripheral T Ce... | Tumor biopsy Peripheral bloo... Lymphotrack TCR... | 18 Years - | Washington University School of Medicine | |
| Shave Margins in Breast Conservation Therapy | NCT02462200 | Breast Cancer Cancer of Breas... Cancer of the B... | Breast-conservi... Cavity shave ma... BREAST-Q Questi... 3-D breast imag... Indocyanine gre... Intraoperative ... Peripheral bloo... | 18 Years - 85 Years | Washington University School of Medicine | |
| Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors | NCT03988283 | Pediatric Recur... | Personalized ne... Papivax Biotech... Peripheral bloo... | - 25 Years | Washington University School of Medicine | |
| Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | NCT04643379 | Recurrent Head ... Metastatic Head... | Olaparib Pembrolizumab Carboplatin Peripheral bloo... | 18 Years - | Washington University School of Medicine | |
| Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | NCT04643379 | Recurrent Head ... Metastatic Head... | Olaparib Pembrolizumab Carboplatin Peripheral bloo... | 18 Years - | Washington University School of Medicine | |
| Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells | NCT00353483 | Breast Neoplasm... | Peripheral bloo... Breast tissue c... Bone marrow bio... | 18 Years - | Washington University School of Medicine | |
| Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC | NCT03689855 | Non-small Cell ... Non Small Cell ... NSCLC | Ramucirumab Atezolizumab Peripheral bloo... Biopsy | 18 Years - | Washington University School of Medicine | |
| Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy | NCT03199040 | Triple Negative... Triple Negative... TNBC - Triple-N... Triple-negative... | Durvalumab Neoantigen DNA ... TDS-IM system (... Peripheral bloo... | 18 Years - | Washington University School of Medicine | |
| Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors | NCT03068832 | Pediatric Brain... | Personalized pe... Poly ICLC Peripheral bloo... | - 21 Years | Washington University School of Medicine | |
| Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy | NCT03199040 | Triple Negative... Triple Negative... TNBC - Triple-N... Triple-negative... | Durvalumab Neoantigen DNA ... TDS-IM system (... Peripheral bloo... | 18 Years - | Washington University School of Medicine | |
| Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC | NCT03689855 | Non-small Cell ... Non Small Cell ... NSCLC | Ramucirumab Atezolizumab Peripheral bloo... Biopsy | 18 Years - | Washington University School of Medicine | |
| Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy | NCT03199040 | Triple Negative... Triple Negative... TNBC - Triple-N... Triple-negative... | Durvalumab Neoantigen DNA ... TDS-IM system (... Peripheral bloo... | 18 Years - | Washington University School of Medicine | |
| Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma | NCT03389477 | Head and Neck S... | Palbociclib Cetuximab Cisplatin Intensity-Modul... Tumor biopsy Peripheral bloo... | 18 Years - | Washington University School of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
